BSW Wealth Partners Boosts Holdings in Merck & Company, Inc. (MRK)

BSW Wealth Partners raised its position in shares of Merck & Company, Inc. (NYSE:MRK) by 7.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,778 shares of the company’s stock after acquiring an additional 325 shares during the period. BSW Wealth Partners’ holdings in Merck & were worth $306,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Boston Partners lifted its stake in shares of Merck & by 2.6% in the first quarter. Boston Partners now owns 19,935,016 shares of the company’s stock worth $1,266,671,000 after acquiring an additional 500,476 shares in the last quarter. Legal & General Group Plc increased its holdings in Merck & by 1.3% in the second quarter. Legal & General Group Plc now owns 14,564,388 shares of the company’s stock valued at $933,445,000 after buying an additional 192,348 shares during the last quarter. Clearbridge Investments LLC increased its holdings in Merck & by 0.6% in the first quarter. Clearbridge Investments LLC now owns 13,414,669 shares of the company’s stock valued at $852,368,000 after buying an additional 77,344 shares during the last quarter. Sanders Capital LLC increased its holdings in Merck & by 4.0% in the second quarter. Sanders Capital LLC now owns 12,052,595 shares of the company’s stock valued at $835,462,000 after buying an additional 458,950 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Merck & by 0.4% in the first quarter. PNC Financial Services Group Inc. now owns 9,821,563 shares of the company’s stock valued at $624,064,000 after buying an additional 41,748 shares during the last quarter. 72.98% of the stock is owned by hedge funds and other institutional investors.

In other Merck & news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.25% of the stock is owned by corporate insiders.

Merck & Company, Inc. (NYSE:MRK) opened at $54.37 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.57. The company has a market cap of $147,855.20, a price-to-earnings ratio of 13.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.78. Merck & Company, Inc. has a 1 year low of $53.63 and a 1 year high of $66.80.

Merck & (NYSE:MRK) last posted its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 27.08%. The firm had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. During the same period in the prior year, the business posted $1.07 earnings per share. The business’s quarterly revenue was down 2.0% on a year-over-year basis. equities analysts anticipate that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

Several brokerages recently weighed in on MRK. BMO Capital Markets reissued a “buy” rating and issued a $72.00 price objective on shares of Merck & in a report on Friday, September 8th. BidaskClub lowered Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Morgan Stanley lowered Merck & from an “overweight” rating to an “equal weight” rating and set a $56.00 target price for the company. in a report on Monday, October 30th. Credit Suisse Group reaffirmed an “outperform” rating and set a $74.00 target price (down from $75.00) on shares of Merck & in a report on Tuesday, September 5th. Finally, UBS AG lowered their target price on Merck & from $72.00 to $67.00 and set a “buy” rating for the company in a report on Monday, October 30th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $66.87.

ILLEGAL ACTIVITY NOTICE: “BSW Wealth Partners Boosts Holdings in Merck & Company, Inc. (MRK)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/11/23/bsw-wealth-partners-boosts-holdings-in-merck-company-inc-mrk.html.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

What are top analysts saying about Merck & Company Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck & Company Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit